MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

YM758

CAS No. : 312752-85-5

MCE 站：YM758

产品活性：YM758 是一个特异性的窦房结 I_f 电流抑制剂。

研究领域：Membrane Transporter/Ion Channel

作用靶点：Sodium Channel  |  Potassium Channel

In Vitro: The inhibitory effect of YM758 on [³H]MPP uptake via human/rat organic cation transporters (hOCT1/rOct1) is investigated. YM758 inhibits rOct1- and hOCT1-mediated [³H]MPP uptake in a concentration-dependent manner with IC₅₀ values of 23.8 and 40.5 μM, respectively. The IC₅₀ value of YM758 for [¹⁴C]Metformin uptake via rOct1 may be estimated below 10 μM in the same way, whereas that is much smaller than that for [³H]MPP uptake. In addition, the inhibitory effect of YM758 on [³H]E₂17βG uptake via OATP1B1 and OATP1B3 is investigated. YM758 inhibits OATP1B1-mediated [³H]E₂17βG uptake in a concentration-dependent manner with a IC₅₀ value of 13.0 μM. YM758 has no inhibitory effect on OATP1B3-mediated [³H]E₂17βG uptake.

In Vivo: After a single intravenous administration of 0.03, 0.1, and 0.3 mg/kg to tachycardia-induced beagles, YM758 plasma concentrations rapidly decrease with t_1/2 values of 1.62, 4.93, and 1.63 h, respectively. At the corresponding doses, the CL_tot values amount to 1.71, 1.69, and 1.48 L/h/kg, and Vd_ss values are 3.19, 5.78, and 2.94 L/kg, respectively. Because the plasma concentration 24 h after administration is quantified only in the 0.1 mg/kg dosing group, the larger values of t_1/2 and Vd_ss are obtained compared with those in other dosing groups. The PK profile of YM758 in tachycardia-induced dogs appeares to be linear within the dose range of 0.03 to 0.3 mg/kg. The CL_tot of YM758 in the blood basis (CL_b,dog) is estimated to be 1.47 to 1.69 L/h/kg. The radioactivity in the rat eyeballs after dosing ¹⁴C-YM758 is extracted with a mixture of 2 mol/L hydrochloric acid and Methanol (5:95, v/v); the radioactivity recovery is 97.1% at 4 h and 67.1% at 24 h. The HPLC recovery of radioactivity from the extracted samples is 90.6 and 100.6% at 4 and 24 h, respectively. In the eyeball at 4 h after administration, YM758 (the unchanged drug) is the main compound detected (66.7%), and the metabolites YM-252124 (14.5%), YM-394111 (2.4%), and YM-234903 (1.8%) are also observed.

相关产品：Nigericin sodium salt  |  BAPTA-AM  |  EIPA  |  Amiloride hydrochloride  |  Monensin sodium salt  |  Rosuvastatin Calcium  |  SKF-96365 hydrochloride  |  Glibenclamide  |  Carbamazepine  |  SCH-23390 hydrochloride  |  Tetrandrine  |  Amiodarone hydrochloride  |  5-(N,N-Hexamethylene)-amiloride  |  Riluzole  |  TRAM-34  |  Ifenprodil tartrate  |  Minoxidil  |  Diazoxide  |  20(S)-Ginsenoside Rg3  |  Senicapoc  |  Tannic acid  |  DCPIB  |  Lidocaine  |  Amitriptyline hydrochloride  |  Astemizole  |  Ketanserin  |  Quinine  |  Cariporide  |  E-4031  |  Terfenadine

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。